Your Vote Counts! CYTOSORBENTS CORPORATION C/O BROADRIDGE P.O. BOX 1342 BRENTWOOD, NY 11717 CYTOSORBENTS CORPORATION 2022 Annual Meeting Vote by June 6, 2022 11:59 PM ET You invested in CYTOSORBENTS CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 7, 2022. Vote Virtually at the Meeting* June 7, 2022 10:00 a.m., Eastern time Virtually at: www.virtualshareholdermeeting.com/CTSO2022 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number V1.1 For complete information and to vote, visit www.ProxyVote.com Control # D78619-P70391 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 24, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

+

THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. Voting Items Board Recommends D78620-P70391 1. To elect the following nominees to serve as directors: Nominees: 1d. Michael G. Bator, MBA 1a. Phillip P. Chan, MD, PhD 1b. Al W. Kraus 1e. Alan D. Sobel, CPA 1c. Edward R. Jones, MD, MBA 1f. Jiny Kim, MBA 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K. 3. To ratify the appointment of WithumSmith+Brown, PC as CytoSorbents Corporation’s independent auditors to audit CytoSorbents Corporation’s financial statements for the fiscal year ending December 31, 2022. 4. To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof. For For For For For For For For